Sumfest J M, Burns M W, Mitchell M E
Department of Pediatric Urology, Children's Hospital and Medical Center, Seattle, Washington.
Urology. 1993 Sep;42(3):309-12. doi: 10.1016/0090-4295(93)90621-g.
The treatment of autosomal recessive polycystic kidney disease (ARPKD) is evolving. Overall prognosis is difficult to determine, but most neonates without severe pulmonary hypoplasia will survive. It is difficult to predict which neonates with ARPKD requiring immediate ventilatory support have pulmonary hypoplasia incompatible with survival. Massively enlarged kidneys restricting diaphragmatic excursion can cause respiratory distress in addition to pulmonary hypoplasia. Three infants with ARPKD underwent bilateral nephrectomies and institution of peritoneal dialysis in an attempt to improve ventilatory status and assess long-term pulmonary function. Two children are alive at twelve and thirty months postoperatively and awaiting renal transplantation. One infant died of acute cardiorespiratory complications.
常染色体隐性多囊肾病(ARPKD)的治疗方法正在不断发展。总体预后难以确定,但大多数没有严重肺发育不全的新生儿能够存活。很难预测哪些需要立即进行通气支持的ARPKD新生儿存在无法存活的肺发育不全情况。除了肺发育不全外,肾脏的极度肿大限制膈肌运动可导致呼吸窘迫。三名患有ARPKD的婴儿接受了双侧肾切除术并进行了腹膜透析,以试图改善通气状况并评估长期肺功能。两名儿童在术后12个月和30个月时存活,正在等待肾移植。一名婴儿死于急性心肺并发症。